Results 91 to 100 of about 18,744,545 (170)
Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [11C]UCB-J and [18F]FDG PET Study [PDF]
Background: Patients with Lewy body diseases exhibit various degrees of cortical and subcortical hypometabolism. However, the underlying causes behind this progressive hypometabolism remain unresolved.
Borghammer P +9 more
core +1 more source
Higher drinking frequency corresponds to lower synaptic density in people with alcohol use disorder
BACKGROUND Chronic alcohol use leads to synaptic dysfunction in preclinical studies. However, whether in vivo synaptic density deficits are found in people with alcohol use disorder (AUD) remains unclear.METHODS Thirty-two people with AUD (n = 17 women ...
Yasmin Zakiniaeiz +11 more
doaj +1 more source
Measurement of synaptic density in Down syndrome using PET imaging: a pilot study
Down syndrome (DS) is the most prevalent genetic cause of intellectual disability, resulting from trisomy 21. Recently, positron emission tomography (PET) imaging has been used to image synapses in vivo.
Alexandra DiFilippo +13 more
doaj +1 more source
SV2A PET imaging in human neurodegenerative diseases
This manuscript presents a thorough review of synaptic vesicle glycoprotein 2A (SV2A) as a biomarker for synaptic integrity using Positron Emission Tomography (PET) in neurodegenerative diseases.
Mahsa Shanaki Bavarsad, Lea T. Grinberg
doaj +1 more source
Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study. [PDF]
Holland N +13 more
europepmc +1 more source
SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes [PDF]
Introduction: We investigated hippocampal synaptic density using synaptic vesicle 2A positron emission tomography (PET), and its association with amyloid beta (Aβ) and cognitive performance in healthy apolipoprotein E (APOE) ε4 carriers.Methods: Synaptic
Tuisku, Jouni +8 more
core +1 more source
Parkinson's disease (PD) is a neurodegenerative disease characterised by molecular and structural brain changes detectable through advanced imaging. Understanding alterations in neurotransmitter systems and synaptic density, and their clinical relevance,
Julia J. Schubert +9 more
doaj +1 more source
Dose reduction for synaptic density PET imaging in Parkinson’s disease
Objective: Dynamic PET imaging with 11C-UCB-J enables in vivo quantification of synaptic vesicle glycoprotein 2A (SV2A), with prior reports of lower synaptic density in areas such as the brainstem nuclei and substantia nigra (SN) in Parkinson’s disease ...
Andi Li +7 more
doaj +1 more source

